Prostate Cancer Outcomes After Ga68-PSMA-PET Imaging

By Tian Zhang, MD - Last Updated: June 10, 2024

Tian Zhang, MD, of UT Southwestern Medical Center, expands on treatment outcomes for patients with prostate cancer after imaging with Ga68-PSMA-PET.

She details differences in PSA PFS and time to castration resistance between patients with PSMA+/CT-negative and PSMA+/CT-positive prostate cancer on Ga68-PSMA-PET/CT imaging.

View her other comments on Seq-Cabo: High-Dose Cabozantinib or Nivolumab Combination After Progression in Advanced RCC.

Co-PSMA Trial: Head-to-Head Comparison of 64Cu-SAR-bis-PSMA vs 68Ga-PSMA-11

Louise Emmett, MDProstate Cancer Diagnostics | March 24, 2025

Dr. Emmett discusses the Co-PSMA trial, comparing ⁶⁴Cu-SAR-bisPSMA and ⁶⁸Ga-PSMA-11 for detecting prostate cancer ...

Patient Perceptions of Germline Genetic Testing Benefits for Prostate Cancer

Emily MenendezProstate Cancer Diagnostics | March 13, 2025

Germline genetic testing is underused for patients with prostate cancer, despite many being eligible for the procedure.

ASCO Releases New Recommendations on Germline and Somatic Testing for Metastatic PCa

Emily MenendezProstate Cancer Diagnostics | January 28, 2025

Patients with metastatic PCa are recommended to undergo both germline and somatic DNA sequencing using panel-based assays.

Precision Medicine in Prostate Cancer: A Multidisciplinary Discussion

Jacob Ark, MDCRPC | February 3, 2025

Expert panel discusses diagnostic criteria, precision medicine, and PSMA imaging in managing metastatic prostate cancer.

Clarity Pharmaceuticals Receives FDA Fast Track Designation for Cu-64 SAR-bisPSMA Prostate Cancer Imaging Agent

Brandon TwyfordProstate Cancer Diagnostics | January 24, 2025

The FDA's Fast Track Designation enables expedited development of 64Cu-SAR-bisPSMA for recurrent prostate cancer imaging.

Prostate Cancer Outcomes After Ga68-PSMA-PET Imaging

Related Posts